Effect of Screening with Multicancer Early-Detection Test on Late-Stage Cancer Diagnosis
Source: View publication →
In a large randomized trial in England, population screening with a multicancer early-detection blood test added to usual care did not significantly reduce the combined incidence of stage III or IV cancers across 12 prespecified types, though a potential signal of benefit was observed for stage IV cancers alone.
Key Findings
Study Design
Study Limitations
Clinical Significance
This landmark trial provides the first large-scale randomized evidence evaluating the clinical utility of blood-based multicancer early-detection (MCED) screening. While the test is safe, its failure to meet the primary endpoint of reducing stage III/IV cancers challenges its immediate population-level deployment. However, a potential 14% reduction in stage IV cancers suggests the assay might still demonstrate meaningful clinical value with longer-term follow-up.
Historical Context
Blood-based multicancer early-detection (MCED) tests, which analyze circulating cell-free DNA to detect cancer signals before symptoms arise, generated immense enthusiasm based on their high specificity in early observational studies like PATHFINDER. However, whether implementing these tests at a population level could genuinely downstage cancer diagnoses or reduce late-stage disease burden remained a theoretical gap. The NHS-Galleri trial was launched to answer this critical question, providing rigorous Phase III data to determine if highly sensitive liquid biopsy screening truly shifts the epidemiological presentation of advanced malignancies.
Guided Discussion
High-yield insights from every perspective
How do multicancer early-detection (MCED) blood tests typically detect the presence of cancer, and what is the biological basis for the release of these biomarkers into the bloodstream?
Key Response
Tests like these rely on detecting cell-free DNA (cfDNA) and specific methylation patterns. These are shed into the bloodstream by tumor cells undergoing apoptosis or necrosis. Understanding cfDNA kinetics is foundational for understanding the test's mechanism and its reliance on tumor burden for detection sensitivity.
If a patient has a positive MCED test but normal age-appropriate screening (e.g., normal colonoscopy and mammogram), what is the appropriate next step in clinical management, and what are the risks of this diagnostic cascade?
Key Response
Residents must manage the downstream effects of screening. A positive MCED without an obvious primary requires extensive diagnostic workup, often including whole-body imaging like PET/CT. This introduces risks of radiation exposure, invasive biopsies of benign incidentalomas, procedural complications, and significant patient anxiety without guaranteed clinical benefit.
The study found no significant reduction in combined stage III and IV cancers, but a potential signal for stage IV alone. How might the biology of tumor shedding and the sensitivity of cfDNA-based tests explain this discrepancy?
Key Response
Tumor fraction in blood correlates strongly with tumor burden and vascular invasion. Stage IV tumors shed vastly more cfDNA, making MCED tests highly sensitive for them. In contrast, they may lack the analytical sensitivity to consistently catch stage II or III tumors before they progress, explaining why only the incidence of stage IV disease showed a potential shift.
Given that the MCED test did not significantly reduce the primary endpoint in this trial, how should you counsel a healthy, asymptomatic patient who requests this test out of pocket based on commercial marketing?
Key Response
Attendings must navigate direct-to-consumer marketing using evidence-based shared decision-making. Counseling should emphasize the lack of proven stage-shift or mortality benefit, the high potential for false positives leading to harmful diagnostic cascades, and the critical importance of not replacing standard proven screening modalities like mammography or colonoscopy.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
The trial used the combined incidence of stage III or IV cancers as a surrogate primary endpoint instead of cancer-specific mortality. What are the statistical and epidemiological limitations of using stage shift as a surrogate endpoint for mortality in this context?
Key Response
Stage shift does not guarantee a mortality benefit due to lead-time bias and length-time bias. Furthermore, shifting a cancer from stage IV to stage III might not change overall survival if the underlying tumor biology remains highly aggressive and incurable at stage III, making mortality the only true definitive endpoint.
The authors reported a non-significant primary endpoint but highlighted a potential signal of benefit for stage IV cancers alone. As an editor, how do you evaluate the validity of this secondary finding to prevent scientific spin?
Key Response
Emphasizing a secondary endpoint when the primary fails is a major red flag for spin. Editors must require strict adherence to the pre-specified statistical analysis plan, looking for alpha-spending adjustments for multiple comparisons, and ensure the abstract appropriately frames the stage IV finding as hypothesis-generating rather than conclusive evidence of efficacy.
Based on this trial's failure to meet its primary endpoint, how does this evidence impact current recommendations for population-level MCED screening, and how does it align with current USPSTF stances?
Key Response
The USPSTF currently has no recommendation supporting MCED testing for routine screening due to insufficient evidence. This negative primary outcome reinforces that stance, demonstrating that MCED should not be incorporated into clinical guidelines until large-scale trials demonstrate a definitive mortality benefit that outweighs the harms of overdiagnosis and false positives.
Clinical Landscape
Noteworthy Related Trials
National Lung Screening Trial (NLST)
Tested
Low-dose computed tomography (LDCT) screening
Population
High-risk current or former heavy smokers aged 55 to 74 years
Comparator
Single-view posteroanterior chest radiography
Endpoint
Lung-cancer mortality
DETECT-A Trial
Tested
Blood-based multicancer test (CancerSEEK) combined with PET-CT
Population
Women aged 65 to 75 years with no prior history of cancer
Comparator
Standard of care alone
Endpoint
Safety and feasibility of intervening on positive blood tests
PATHFINDER Trial
Tested
Methylation-based cfDNA multicancer early detection (MCED) test
Population
Adults aged 50 years and older without active cancer
Comparator
Standard of care screening
Endpoint
Diagnostic resolution time and positive predictive value
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis